Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
PURPOSE: The aim of this prospective, phase II trial was to determine the response of muscle-invasive bladder cancer (MIBC) to concurrent chemoradiotherapy of weekly gemcitabine with 4 weeks of radiotherapy (RT; GemX). PATIENTS AND METHODS: Fifty patients with transitional cell carcinoma, stage T2-3...
Main Authors: | Choudhury, A, Swindell, R, Logue, J, Elliott, P, Livsey, J, Wise, M, Symonds, P, Wylie, J, Ramani, V, Sangar, V, Lyons, J, Bottomley, I, McCaul, D, Clarke, N, Kiltie, A, Cowan, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2011
|
Similar Items
-
A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
by: Choudhury, A, et al.
Published: (2010) -
Pre-hospital antibiotics for open fractures: Is there time? A descriptive study
by: J.K. McCaul*, et al.
Published: (2013-12-01) -
Gemcitabine as a Chemoradiosensitiser in Bladder Cancer
by: Kerr, M, et al.
Published: (2012) -
Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits
by: Ray, KJ, et al.
Published: (2015) -
Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
by: Ray, K, et al.
Published: (2015)